arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ZEVRA THERAPEUTICS, INC.

ZVRA
$11.31 ▼ -0.27 (-2.29%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
14 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
57
Health
Fair
Bullish
auto_awesome

Analytical Summary

ZEVRA THERAPEUTICS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $625.6M
Dividend Yield —
Revenue Growth 350.9% ↗
Op. Margin -59.1% ↗
ROIC -27.9% ↗
FCF / Share $-0.04 ↗
Trailing P/E 8.1x
Price / Book 4.2x
FCF Yield —
Debt / Equity 0.40
info Valuation on last close. End-of-day price, Sep 23, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$106.47M
↑ +350.9% —
Net Income Profit after all expenses
$83.23M
↑ +178.9% —
Operating Margin Operating profit as % of sales
-59.1%
↑ +84.0% 4th
FCF / Share Free cash flow per share
$-0.04
↑ +97.1% —
Long-Term Debt Long-term obligations
$61.93M
↑ +4.1% —
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
41
Returns
97
Financial Health
43
Cash Quality ↑
21

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 52 quarters